Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2001

View Archived Issues

Lilly highlights significant events over last three months; selected late-stage compounds updated

Pharmacia highlights key first-year milestones at annual meeting

QS-21 permits reduced antigen dose in candidate HIV-1 vaccine

Antiatherogenic effects of J-861 attributed to potent antioxidant, free radical-scavenging actions

Ultrapotent PARP inhibitor designed at Inotek with potential in stroke and diabetic complications

Iomed's phase III trial for ProDex does not reach primary endpoint

NS-3623: a long-acting, reversible Cl conductance blocker for sickle cell disease

Novo Nordisk licenses GH-stimulating compounds to Rejuvenon

FibroGen awarded SBIR grant for development of antiscarring agent

Data presented on two classes of compounds from Celgene's cytokine inhibitor platform

Tularik provides clinical update

Selective NK2 and combined NK2/NK3 antagonists derived from selective NK3 antagonists at GSK

Plant-derived compound possesses antiherpes activity in vivo

Vivus reports progress of products in clinical development

Regeneron provides Q1 update

Inflazyme antiinflammatory compounds head for clinical trials

Nitroimidazole imaging agents for ischemic sites designed by Pola Chemical

Boehringer Ingelheim presents new cathepsin inhibitors in recent patent

New kinase inhibitors under study at Pfizer

DuPont synthesizes compounds for disorders related to beta-amyloid production

Hectorol approved by Canadian health authorities

PTP inhibitors emerge from Novo Nordisk/Ontogen collaboration

Major global cancer vaccine collaboration announced by Merck and Biomira

Series of polynucleotides encoding human GPCRs discovered at Pfizer

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...